[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lung-metastases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lung-metastases":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,44,74,103,132,166,195],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100631361","phase-3-evaluation-of-the-safety-and-efficacy-of-abenacianine-vgt-309-to-identify-cancer-in-subjects-undergoing-surgery-for-cancer-in-the-lung-100631361",false,"NCT07499674","Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung","A Phase 3, Multi-center, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Abenacianine (VGT-309), a Tumor-Targeted, Activatable Fluorescent Imaging Agent, to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung - VISUALIZE 2","VISUALIZE-2","Inclusion Criteria:\n\n1. Be willing and able to sign the informed consent and comply with study procedures.\n2. Be at least 18 years of age.\n3. Be scheduled for or planning to have a surgical resection of a lung lesion or mass with diagnostic and\u002For curative intent.\n4. Meet all requirements for the planned surgery based on opinion of the surgeon, anesthesiologist, and\u002For other consulting physician.\n5. Be able to meet the following conditions:\n\n   1. Female participants must be of non-childbearing potential, or,\n   2. If of childbearing potential, be non-pregnant or non-lactating and agree to use highly effective contraception from screening through Day 30 after treatment.\n   3. Male participants, if not surgically sterilized, and if engaging in sexual intercourse with a female partner of childbearing potential, must be willing to use highly effective contraception from screening through 30 days after dosing.\n6. Have not participated in an interventional clinical trial within the last 30 days.\n\nExclusion Criteria:\n\n1. They have a known allergy or reaction to radiographic contrast agents, ICG, or any component of abenacianine.\n2. They have received chemotherapy, immunotherapy or radiotherapy within 4 weeks prior to study enrollment.\n3. They have any other co-morbidity or habit that the Investigator believes will interfere with their ability to comply with and complete the study. They are not a candidate for standard of care surgery based on opinion of the surgeon, anesthesiologist, or other consulting physician.\n4. They are prisoners, institutionalized individuals, or are unable to consent for themselves.","ALL","18 Years",{"count":20,"type":21},132,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This is a Phase 3, multi-center, randomized and intrasubject controlled study to evaluate the safety and efficacy of abenacianine for injection, a tumor-targeted, activatable fluorescent imaging agent, to identify cancer using NIR imaging in participants undergoing surgery for cancer in the lung. Approximately 132 partiipants will be enrolled to ensure a minimum of 115 evaluable participants receiving abenacianine and undergoing NIR imaging and a control group of 12 participants who will receive abenacianine but no NIR imaging.",[27,28],"Lung Cancer","Lung Metastases",[27,30],"Metastatic Cancer in Lung","RECRUITING","2026-05-28",{"date":34,"type":35},"2026-05-29","ACTUAL",{"date":37,"type":35},"2026-03-31",{"date":39,"type":21},"2027-03",{"name":41,"class":42},"Vergent Bioscience, Inc.","INDUSTRY",9,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100486204","phase-1-in-vivo-lung-perfusion-ivlp-for-colorectal-cancer-metastatic-to-lung-100486204","NCT05611034","In Vivo Lung Perfusion (IVLP) for Colorectal Cancer Metastatic to Lung","In Vivo Lung Perfusion (IVLP) as an Adjuvant Treatment for Patients With Resectable Pulmonary Metastases of Colorectal Cancers","Inclusion Criteria:\n\n1. Diagnosis of Colorectal Carcinoma\n2. Presence of bilateral pulmonary metastases\n3. 3 or more lung lesions in total\n4. Age 70 years or less\n5. ECOG 0-2\n6. Absence of extra-pulmonary disease, except liver metastases suitable to curative treatment.\n\nExclusion Criteria:\n\n1. Patient has previously received more than 1000 mg of oxaliplatin\n2. Left Ventricular Ejection Fraction \\\u003C50%\n3. History of significant pulmonary disease or pneumonitis\n4. Pregnant or lactating females\n5. Age 71 or older, or less than 18 years\n6. Inability to understand the informed consent process\n7. Hypersenstivity to oxaliplatin\n8. Patients with Heparin-induced thrombocytopenia (HIT)\n9. Patients who cannot receive cefazolin or methylprednisolone due to allergy or another reason can be included but will not receive the drug they cannot tolerate\n10. Current participation in another therapeutic clinical trial","70 Years",{"count":53,"type":21},10,[55],"PHASE1","This study is investigating a new technique for delivering chemotherapy directly into the lungs at the time of surgery. Delivering chemotherapy directly to the lungs could potentially kill any microscopic cancer cells that are present in the lungs at the time of surgery, while sparing other major organs in the body from the side effects of chemotherapy. This technique is called In Vivo Lung Perfusion (IVLP). At the University Health Network, this IVLP technique has been used recently in a Phase I study in patients with sarcoma, and we are now expanding on that experience to include patients with colorectal metastases. The purpose of this study is to test the safety of the IVLP technique and find the dose that seems right in humans. Participants are given oxaliplatin into one lung via IVLP and are watched very closely to see what side effects they have and to make sure the side effects are not severe. If the side effects are not severe, then more participants are asked to join the study and are given a higher dose of oxaliplatin. Participants joining the study later on will get higher doses of oxaliplatin than participants who join earlier. This will continue until a dose is found that causes severe but temporary side effects. Doses higher than that will not be given. The other lung will not be infused with anything, so that we can limit unforeseen toxicity to a single lung and see if one lung does better than the other.",[28,58,59],"Colorectal Cancer Metastatic","Colorectal Cancer",[61,62],"IVLP","metastatic","2026-04-28",{"date":65,"type":35},"2026-04-29",{"date":67,"type":35},"2023-02-06",{"date":69,"type":21},"2032-01-01",{"name":71,"class":72},"University Health Network, Toronto","OTHER",1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":73},"100566167","oxford-pleural-embolisation-trial-100566167","NCT06651658","Oxford Pleural Embolisation Trial","Pleural Blood Patch for Lung Ablation: a Randomised Trial (Oxford Pleural Embolisation Trial - OxPET)","OxPET","Inclusion Criteria:\n\n* Clinically indicated for lung ablation.\n* Willing and capable of giving informed consent.\n* Aged 18 years or above.\n\nExclusion Criteria:\n\n* Unable to proceed to lung ablation procedure.\n* 3 or more lung lesions to be ablated in the same setting.",{"count":83,"type":21},106,[85],"NA","Thermal ablation is an established treatment for lung cancer. It involves insertion of a applicator under image guidance into a lung tumour and destroying it with radiofrequency, microwave or cryotherapy. One of the common side effects is pneumothorax, which is a leak of gas from the lungs when it punctured. Air leak necessitates placement of a drainage tube in more than half of patients undergoing the procedure. The drain can be associated with some morbidity including pain, reduced mobility, prolonged hospital stay and infection Pleural embolization refers to the injection of substances to the linings of the lung to seal air leakage. There is published evidence in using pleural embolization with autologous blood (blood drawn up from the patient's veins) to prevent pneumothorax in patients undergoing lung biopsies. This technique is also known as pleural blood patch (PBP). A study involving more than 4000 patients found that PBP reduced the rates of pneumothorax by 35% and drain placement by 55% in lung patients. A study using prophylactic gelfoam torpedo embolization for radiofrequency ablation showed significant reduction in chest drain rates.\n\nIn this study, investigators plan to evaluate the PBP using a tandem needle technique in patients undergoing lung ablation at the Oxford Thermal Ablation Service, one of the largest units in the country performing about 200 ablations per year, mostly microwave ablations. Patients will be randomized to receive lung ablation with or without the PBP.\n\nThe PBP technique is easy to learn, enjoys high technical success rates and does not expose the patient to any significant additional risk.\n\nThe primary outcome is the chest drains rates in the two trial groups:\n\n1. patients undergoing lung ablation without PBP and\n2. patients undergoing lung ablation with PBP. Other outcomes that would be measured include the volume of gas leakage on Computed Tomography (CT) imaging, safety profile, length of stay, feasibility of same day discharge, patient oriented outcomes including validated pain score, and institution oriented outcomes including medical costs.\n\nA positive trial could significantly reduce the side effect profile of lung ablation and hasten the patient's recovery. There could be significant savings in healthcare costs as the procedure may become safe to perform as a day procedure as opposed to an overnight procedure.",[27,28],[89,90,91,92,93],"lung cancer","lung metastases","lung ablation","pleural embolisation","Pleural blood patch","2026-02-02",{"date":96,"type":35},"2026-02-04",{"date":98,"type":35},"2024-11-24",{"date":100,"type":21},"2027-09",{"name":102,"class":72},"Oxford University Hospitals NHS Trust",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":113,"phases":4,"briefSummary":114,"conditions":115,"keywords":118,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":73},"100601630","development-of-innovative-preclinical-ex-vivo-models-for-the-study-of-sarcomas-and-metastases-from-solid-tumors-100601630","NCT07112989","Development of Innovative Preclinical Ex Vivo Models for the Study of Sarcomas and Metastases From Solid Tumors","PREMOD","Inclusion Criteria:\n\n* Patients (male or female) diagnosed with sarcoma or with bone or lung metastases from solid tumors\n* Age between 0 and 85 years\n* Availability of sufficient and adequate biological material (tumor tissue and\u002For blood)\n* Signed informed consent for biobanking (BIOTUM)\n* Signed informed consent for use of tissue and blood samples in this study\n\nExclusion Criteria:\n\n* Diagnosis other than sarcoma or metastases from solid tumors\n* Missing signed informed consent(s)","85 Years",{"count":112,"type":21},125,"OBSERVATIONAL","The goal of this observational study is to learn how tumor tissue and blood samples from patients with sarcomas or metastases can be used to create laboratory models that help researchers study cancer behavior and test new treatments. Participants diagnosed with sarcoma or with bone or lung metastases from solid tumors will donate leftover tumor tissue and blood collected during their regular medical care. These samples will be used in the lab to build 3D models of the tumor, test drugs, and identify genetic and molecular markers. No treatments or procedures will be given as part of the study.",[116,117,28],"Bone and Soft Tissue Tumors","Bone Metastases From Solid Tumors",[119,120,121,122],"Sarcomas","Bone metastases","Lung metastases","Preclinical models","2025-08-01",{"date":125,"type":35},"2025-08-08",{"date":127,"type":35},"2024-09-23",{"date":129,"type":21},"2031-09-23",{"name":131,"class":72},"Istituto Ortopedico Rizzoli",{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":140,"enrollmentInfo":141,"targetDuration":143,"studyType":113,"phases":4,"briefSummary":144,"conditions":145,"keywords":150,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":165},"100497317","on-treatment-biomarkers-in-metastatic-colorectal-cancer-for-life-100497317","NCT05755672","On-treatment Biomarkers in Metastatic Colorectal Cancer for Life","On-treatment Biomarkers in Metastatic Colorectal Cancer for Life: The On-CALL Study","On-CALL","Inclusion Criteria:\n\n* Clinical diagnosis of synchronous metastatic colorectal cancer, planned cancer treatment with curative intent at the Skåne University Hospital\n\nExclusion Criteria:\n\n* Not accepting the study inclusion terms (informed consent not obtained)\n* Age below or above the age limit","110 Years",{"count":142,"type":21},100,"10 Years","By virtue of an increased strategic use of cytotoxic and biological agents, and more options for locoregional treatment, the survival of patients with metastatic colorectal cancer (mCRC) has improved considerably in the past decades. The personalized approach to systemic treatment is further aided by the use of complementary molecular biomarkers. However, the evolutionary dynamics of mCRC, a disease harnessed by multiple adaptive genetic alterations towards its final stages, poses a particular challenge to single-sample biomarker analyses and standardized linear treatment protocols. The aim of the On-treatment biomarkers in metastatic ColorectAL cancer for Life (On-CALL) study is to generate further knowledge on the evolutionary progression of mCRC during treatment, and to elucidate the mechanisms underlying the therapeutic failure still seen in a substantial number of patients.\n\nThe On-CALL study is a prospective, single-arm observational study. All patients diagnosed with synchronous mCRC treated with curative intent at Skåne University Hospital will be invited to participate. Clinical and histopathological data will be compiled at study entry. An individual tissue microarray block with samples from resected primary tumours and metastases representing the full extent of the tumour spread will be constructed for each patient. Blood samples will be drawn for biomarker analyses at multiple time points prior to, during and after systemic treatment. DNA sequencing of tumour tissue and circulating tumour DNA (ctDNA) will be performed to define the spatial clonal landscape in primary tumours and metastases, as well as over time.",[146,147,148,149,28],"Metastatic Colorectal Cancer","Chemotherapy Effect","Peritoneal Metastases","Liver Metastasis Colon Cancer",[151,152,153,154,155],"Metastatic colorectal cancer","Chemotherapy","Targeted therapy","Tumor heterogeneity","Tumor evolution","2025-07-14",{"date":158,"type":35},"2025-07-17",{"date":160,"type":35},"2023-03-01",{"date":162,"type":21},"2033-03",{"name":164,"class":72},"Region Skane",2,{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":22,"phases":176,"briefSummary":177,"conditions":178,"keywords":179,"overallStatus":185,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":73},"100501402","colorectal-pulmonary-metastases-pulmonary-metastasectomy-versus-stereotactic-ablative-radiotherapy-100501402","NCT05808790","Colorectal Pulmonary Metastases: Pulmonary Metastasectomy Versus Stereotactic Ablative Radiotherapy","Colorectal Pulmonary Metastases: Pulmonary Metastasectomy Versus Stereotactic Ablative Radiotherapy: a Phase III Multicenter Randomized Controlled Trial","COPPER","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Eastern Cooperative Oncology Group (ECOG)-Performance status 0 - 2\n* Willing to provide informed consent\n* Patients with 1 to 3 lung metastases from colorectal cancer eligible for both a minimally invasive surgical resection and SABR, as assessed by the multidisciplinary tumor board (MDT)\n* Radically treated primary colorectal cancer\n* Patient is able and willing to complete the quality-of-life questionnaires\n* Previous liver metastases are radically treated with curative intent\n* Histologically confirmed malignancy with metastatic disease detected on imaging. Biopsy of metastasis is preferred, but not required.\n\nExclusion Criteria:\n\n* Previous or present metastases outside liver or lungs\n* Concurrent malignant cancer, or history of other malignant cancers within the past 5 years (excluding prespecified low-risk cancers)\n* Hilar or mediastinal lymph node metastases\n* Poor cardiopulmonary function test\n* Inability to treat all colorectal metastases\n* Surgical resection by means of a bilobectomy or pneumonectomy",{"count":175,"type":21},394,[85],"COPPER is an international, multicenter, parallel-arm, phase III randomized controlled trial comparing two local treatment strategies (SABR or metastasectomy) for patients with an indication for local treatment for limited (max. three) colorectal pulmonary metastases",[28,58],[180,181,182,183,184],"Colorectal pulmonary metastases","Pulmonary metastasectomy","Stereotactic radiotherapy","Randomized controlled trial","Colorectal cancer metastases","NOT_YET_RECRUITING","2023-04-10",{"date":188,"type":35},"2023-04-11",{"date":190,"type":21},"2024-01-01",{"date":192,"type":21},"2030-12-31",{"name":194,"class":72},"Amsterdam UMC, location VUmc",{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":201,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":203,"targetDuration":4,"studyType":113,"phases":4,"briefSummary":205,"conditions":206,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":165},"100468116","ai--radiomics-for-stratification-of-lung-nodules-after-radically-treated-cancer-100468116","NCT05375591","AI & Radiomics for Stratification of Lung Nodules After Radically Treated Cancer","Artificial Intelligence & Radiomics for Stratification Of Lung Nodules After Radically Treated Cancer (AI-SONAR)","AI-SONAR","Inclusion Criteria:\n\n* Confirmed history of previous radically or curative-intent treated solid organ cancer within 10 years of new index CT thoracic scan demonstrating a new pulmonary nodule and either of the following:\n\n  * Biopsy confirming previous malignancy with MDT consensus and successful cancer resolution\u002Fremission following anti-cancer treatment on interval imaging or blood assay analysis\n  * Where biopsy was not possible\u002Fconfirmed for previous malignancy, MDT consensus outcome confirming cancer (+\u002F- calculated Herder score \\>80% if applicable) and decision to treat as malignancy with subsequent resolution\u002Fremission following anti-cancer treatment on interval imaging or blood assay analysis\n* Radical treatment for previous cancer defined as either of the following:\n\n  * Surgical resection\n  * Radical radiotherapy or stereotactic beam radiotherapy\n  * Radical chemotherapy\n  * Radical chemo-radiotherapy\n  * Multi-modality treatment with any of the above\n* New pulmonary nodule ground truth known\n\n  * Scan data showing 2-year stability (based on diameter or volumetry) or resolution in cases of benign disease\n  * Scan data showing progressive nodule enlargement or increase in nodule number on interval imaging with MDT consensus (+\u002F- PET with Herder score \\>80% if applicable) determining metastatic disease or new primary malignancy\n  * Biopsy sampling confirming benign disease or malignancy and in cases of malignancy, metastasis or new primary lung cancer\n* CT scan slice thickness ≤ 2.5mm\n* Nodule size ≥ 5mm\n\nExclusion Criteria:\n\n* CT Imaging \\> 10 years old\n* Non-solid haematological malignancies including leukaemia\n* Cases of radically treated primary cancer disease with early oligometastatic recurrence treated radically",{"count":204,"type":21},1000,"This study will assess the utility of radiomics and artificial intelligence approaches to new lung nodules in patients who have undergone radical treatment for a previous cancer.",[207,28,208,27],"Indeterminate Pulmonary Nodules","Second Primary Cancer","2022-05-17",{"date":211,"type":35},"2022-05-24",{"date":213,"type":35},"2021-10-13",{"date":215,"type":21},"2026-11-01",{"name":217,"class":72},"Royal Marsden NHS Foundation Trust"]